SNDX Stock Analysis: Buy, Sell, or Hold?
SNDX - Syndax Pharmaceuticals, Inc.
$20.23
-0.32 (-1.56%)
▼
5d:
-5.86%
30d:
-15.04%
90d:
-1.22%
HOLD
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
SNDX is down 5.9% this week, but smart money is accumulating calls. Top strike: $23 2026-06-18 with 3,045 OI. Call ratio: 97% View Scanner →
Strength: 7.6/10
Get Alerted When SNDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called SNDX this week
0% bullish • 2 bearish
0% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNDX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SNDX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: SNDX is currently trading at $20.23, which is considered oversold relative to its 30-day fair value range of $20.37 to $23.95. From a valuation perspective, the stock is trading at a discount (Forward PE: -88.8) compared to its historical average (126.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SNDX is in a strong uptrend. Immediate support is located at $19.12, while resistance sits at $22.69.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.25 (+94.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNDX is in a strong uptrend. Immediate support is located at $19.12, while resistance sits at $22.69.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.25 (+94.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$20.37 -
$23.95
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
Protect Your Profits
Holding SNDX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 94.0% below Wall St target ($39.25)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$20.37 -
$23.95
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$19.12
Resistance Level
$22.69
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-88.84
Wall Street Target
$39.25
(+94.0%)
Revenue Growth (YoY)
223.6%
Profit Margin
-112.0%
PE vs Historical
-88.8 vs 126.3
CHEAP
Share & Embed Analysis
Last updated: May 18, 2026 7:29 AM ET
Data refreshes hourly during market hours. Next update: 8:29 AM
Data refreshes hourly during market hours. Next update: 8:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Keith A Goldan
SELL
3410 shares
2026-02-09
Michael A Metzger
SELL
17159 shares
2026-02-09
Keith A Goldan
SELL
2082 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 59 HOLD |
Advanced SNDX Option Strategies
Professional options setups generated by AI based on today's SNDX price and gamma walls.
